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INTRODUCTION 
Hemangiomas, including infantile hemangiomas, are the 
most common vascular tumors in children with a 
prevalence of about 10% in Western countries and less 
than this rate in the Asia and Africa.
1,2
 
Although hemangiomas often recover themselves in ages 
7 to 10 years, but can disrupt vital sensory activities 
among the people.
3-5
 
Hemangioma can be small and limited to the skin or as a 
great waste associated with serious complications and 
involving many organs such as the eyes, lungs and air 
passages, liver, gastrointestinal tract or even the brain.
6
 
The most common complication of Hemangiomas is 
injury which was commonly associated with bleeding, 
pain, infection and leaving scarring.
7
 
First line treatment of hemangioma despite having certain 
side effects was long term use of oral corticosteroids. 
More than thirty years glucocorticoids are used for the 
treatment of infantile hemangiomas. Systemic steroids 
can be useful for hemangioma of infancy and can have 
different and non-obvious effects. The rate of Steroids 
was about 84%.
8
 
Recent studies showed the positive effects of propranolol 
on hemangiomas.
9-12
 
ABSTRACT 
 
Background: Hemangioma is the most common vascular tumor in infancy. Recent studies show Propranolol efficacy 
on hemangioma treatment due to its rapid effect and a few side effects. The aim of this study was to assessment the 
efficacy of Propranolol on pediatric haemangioma. 
Methods: This quasi-experimental study was done on 20 children refer to Bu-Ali hospital. Treatment indications 
were multiple hemangioma, organ malfunction and enlarging hemangioma. Treatment of patients was started with 1 
mg/kg/day and then increased to 3 mg/kg/day and continued for 6 month. Collected data analyzed by statistical 
methods in SPSS-19. 
Results: Patients mean age was 23.2 ± 11.2 months. 65% of them were female and 35% were male. The mean size of 
damages was 4.9 ± 3.3 cm. 70% of patients had acceptable response with more than 50% and 30% had partial 
response with less than 50% decrease in size. This effect is similar to corton effect (about 84%) but with less side 
effects. 
Conclusions: This study showed that Propranolol has acceptable effect on decreasing size of hemangioma and could 
be recommended as a first choice of hemangioma treatment. 
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Propranolol is a beta receptor inhibitor drug that act 
randomly. It was discovered in 1950 by James Black.13 In 
recent studies, the beneficial effect of oral propranolol in 
improving hemangioma of infancy period is evident.
14
 
Propranolol side effects include bradycardia, hypotension 
and hypoglycemia.
12,15
 
Hypoglycemia in infants is often asymptomatic, but can 
occasionally cause neurological symptoms.
16
 
As well as both large and small hemangiomas can be 
associated with heart disease with high output that 
propranolol can be cover the signs of heart failure. 
So for optimization of treatment with propranolol 
recommending for doing a primary ecocardiology and 
blood sugar control before treatment and four week after 
is necessary.  
More hemangioma hase size about 0.5-5 cm but they may 
be reaching to 20 cm diameter. The damages can be 
superficial or deep. More superficial damages are purple. 
Approximately 50-60% of hemangioma arent fully 
recovered and associated with changes such as the skin 
telangiectasia, dilated superficial veins, scars or dents or 
hypopigmentation.
17-18
 
The aim of this study was to assessment of Propranolol 
efficacy on less than 15 years pediatric hemangioma. 
METHODS 
This is a quasi-experimental study that has been done on 
20 infants and neonates in pediatrics clinic.  
Of the patients admitted to the hospital, and identify 
children with hemangiomas and children with multiple 
hemangioma, hemangioma in sensitive areas or children 
who were hemangioma large (greater than 5 cm) that they 
are low probability of spontaneous recovery , were 
referred to the Hematology and Oncology for follow-up 
treatment.  
Initially, all patients were evaluated for vital signs and 
blood sugar and echocardiography was performed and 
those patients who have no heart problems and were 
eligible for treatment were treated with propranolol. 
Also, of all the patients before treatment, ultrasound of 
the abdomen and pelvis was performed to assess the 
presence of visceral hemangiomas cell. 
Firstly treatment starts with 1 mg/kg body weight and 
after two week increase to 3 mg/kg. In first week patients 
evaluated by sugar and heart rate that in case of existence 
signs of hypoglycemia and bradycardia therapy was 
stopped. Treatment followed for 6 months and after 
response patients followed for relapse. According to the 
decreasing in the size of hemangioma, the response to 
treatment classified in four group very good (more than 
70%), good (50-75%), moderate (25-50%) and week 
(<25%). 
Collected data analyzed by statistical methods such as 
chi-square and t-test and descriptive statistical methods 
such as table and graph. P<0.05 considered as significant. 
RESULTS 
The mean age of patients was 23.2±11.2 months (range 
from two month-5 year). 7(35%) were in age group 13-24 
months. 65% of infants were girl and rest of them were 
boy. 45% of infants have hemangioma in Body (Figure 
1). 
 
Figure 1: The areas of hemangioma distribution. 
9 patients (45%) have hemangioma in size 2-5 cm. The 
mean of hemangioma in these patients were 4.9±3.3 
(Figure 2). 
 
Figure 2: Size of hemangioma in infants. 
The indication of patients for treatment were Beauty 
problems (13 cases, 65%), speedy growth of hemangioma 
(4 cases, 20%) and impaired organ function (3 cases, 
15%). To search for hemangiomas in other parts of the 
body, ultrasound of the abdomen, pelvis, and liver were 
taken from all patients and in none of the cases was 
observed. Echocardiography was performed in these 
patients and in only two patients had abnormal 
echocardiography (one case PFO and one case TR) and in 
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other patients had normal. For all patients, blood sugar 
and heart rate were done and no side effects were 
observed in treatment with beta-blockers. The mean of 
damages in study start time was 4.9±3.3 cm and this rate 
decreased significantly in end of study and reach to 
1.8±1.1 cm (p=0.001).  
Also results showed that 14 patients (70%) have 
acceptable response to treatment which from them 15% 
has very well and 55% have good response. Results 
showed that there wasn’t any significant relation between 
sex and response of patients. The mean age of patients 
with very good response was 25 months and with good 
response was 22.8 months. There wasn’t any significant 
difference between age of patients and size of damages 
and response rate of patients to treatment.  
DISCUSSION 
Hemangioma is tumors of endothelial cells and the most 
common type of tumor in infants
19
 which the sex ratio 
f/m was varied from 2/1 to 5/1.
20
 
The mean age of patients in this study was 23.2±11.2 
months. Other studies in other places showed that the 
mean age of infants were under one year old which 
wasn’t similar to our study that this result can be related 
to the delay in parent’s referred to treatment of 
infants.
19,21-26
 
65% of infants were girl and 35 % were boy which was 
similar to other studies.
26-28
 
In this study most of patients (70%) have significant 
damage decreasing and a few of them (30%) have week 
response to propranolol. After compare the result of this 
study with other studies seen that most of patients in all 
studies have very good or good response to propranolol 
and there was significant relation between damages size 
and propranolol use. (p=0.001) and only a few of patients 
not response to propranolol. So, this treatment can be one 
of the usual treatments for hemangioma which has been 
increased in the recent years.
19,21-26
 
There weren’t any side effects related to propranolol drug 
use. In other studies, it was found that beta blockers have 
fewer side effects than corticosteroids for patients and 
these drugs are safer than cortisone.
19,21-26,29-30
 
Some of studies compared the propranolol with 
prednisolone in hemangioma treatment and most of them 
resulted that the propranolol is better than prednisol in 
decreasing hemangioma damages.
28-30 
CONCLUSION 
The use of propranolol in children has sufficient 
reduction in size of the hemangioma. Due to the lower 
side effects of the propranolol than corticosteroids, 
propranolol is recommended as a first-line therapy in the 
treatment of hemangioma.  In this study we use only the 
propranolol for treatment hemangioma and we not use 
placebo group or another group for compare the results 
between them. It is recommended that another study in 
this subject must be done in the future and determine the 
effect of propranolol in higher doses. 
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